Dr. Christopher Twelves on Eribulin Mesylate in Combination Therapies for Breast Cancer
Twelves said historically, chemotherapy combinations have been created utilizing empirical evidence, which he says is not a sound rationale for the combinations. He adds that due to certain biological properties of eribulin mesylate, the treatment warrants further investigation as a combination therapy.
Christopher Twelves, MD, professor of Clinical Cancer Pharmacology and Oncology at the Leeds Institute of Cancer and Pathology, St James's Institute of Oncology, Leeds, UK, discusses the potentials for eribulin mesylate (Halaven) to be used in combination with other therapies in the treatment of breast cancer.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
